{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-101688","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.507698+00:00","generated_at":"2026-05-17T02:32:59.871724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Harmony Biosciences raises 2025 revenue guidance after Q3 WAKIX revenue of $239M (+29% YoY)","bullets":["Preliminary Q3 2025 WAKIX net revenue of ~$239M, up 29% year-over-year.","Average patient count rose by ~500 to 8,100 in Q3, the largest quarterly increase ever.","2025 revenue guidance raised to $845-$865M from prior $820-$860M.","Full Q3 2025 earnings and conference call scheduled for November 4, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-101688","json":"https://secwatch.observer/filing/0001104659-25-101688.json","markdown":"https://secwatch.observer/filing/0001104659-25-101688.md","text":"https://secwatch.observer/filing/0001104659-25-101688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/0001104659-25-101688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:32:59.871724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}